Arcus Biosciences (RCUS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting called to order at 8:30 A.M. with board members and executive team present.
Stockholders welcomed and informed of procedures for submitting questions.
Notice of meeting and stockholder list confirmed as distributed and available.
Board and executive committee updates
Attendance included all board members, key executives, and company auditors.
Shareholder proposals
Three proposals presented: election of directors, ratification of auditors, and advisory approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arcus Biosciences
- Q1 2025 net loss was $112M on $28M revenue; cash reserves strong at $1B.RCUS
Q1 20259 Jul 2026 - Castatinopathy demonstrates superior efficacy in RCC trials, targeting major market growth.RCUSH.C. Wainwright 27th Annual Global Investment Conference9 Jul 2026
- Casdatifan outperforms belzutifan in ccRCC, with strong efficacy, safety, and major market potential.RCUSStatus Update8 Jul 2026
- Casdatifan and quemliclustat drive strong clinical and market prospects with pivotal data ahead.RCUSGoldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026
- Casdatifan and quemliclustat drive pipeline growth as Q1 net loss widens to $128M.RCUSQ1 202611 May 2026
- Virtual meeting to vote on directors, auditor, and executive pay, with strong governance and Gilead ties.RCUSProxy filing21 Apr 2026
- Votes will be held on director elections, auditor ratification, and executive pay approval.RCUSProxy filing21 Apr 2026
- Casdatifan and quemliclustat drive late-stage pipeline toward major 2026 milestones and markets.RCUS44th Annual J.P. Morgan Healthcare Conference12 Apr 2026
- Casdatifan achieved 45% ORR and 15.1-month PFS in RCC, with $1B cash supporting pipeline growth.RCUSQ4 20258 Apr 2026